80
late breaking Poster SESSIONS
Monday, 23 June 2014
LP-01
LATE BREAKING
POSTER SESSION
17:15 – 18:45
Hall B
Schizophrenia/Anxiety disorders/
Bipolar disorders
LP-01-001
Selective orexin-1 receptor antagonist attenu-
ates stress induced hyperarousal, CO2-induced
panic associated behavior and cardiovascular
response without hypnotic effect
Pascal Bonaventure, San Diego, USA
P. Johnson, S. Fitz, A. Shekhar, S. Yun, B. Shire-
man, T. Lebold, D. Nepomuceno, B. Lord, J.
Shelton, N. Carruthers, T. Lovenberg, C. Dugovic
LP-01-002
Reduced binding potential of 5-HTT in pa-
tients with obsessive compulsive disorder
even after the treatment with SSRI: [11C]
DASB PET study
Euitae Kim, Gyeonggi-Do, Republic of Korea
P. Jin Woo, B.-H. Kim, S. N. Kim, J. M. Jung,
J. S. Kwon
LP-01-003
The cortisol response to social stress in so-
cial anxiety disorder (SAD)
Martha McKay, Toronto, Canada
O. Vaccarino, R. Levitan, A. Ravindran
LP-01-004
Calcium-dependent intracellular signal path-
ways in primary cultured adipocytes and the
MIR137HG genotype in patients with bipolar
disorder and healthy controls
Hans Agren, Hovas, Sweden
A. Hayashi, K. Le Gal, K. Sodersten, K. Funa
LP-01-005
Cariprazine monotherapy in the treatment of
bipolar depression: A double-blind, placebo-
controlled study
Suresh Durgam, Jersey City, USA
A. Lipschitz, H. Guo, W. Earley, I. Laszlovszky,
G. Németh
LP-01-006
Brain inositol phosphates accumulation is
enhanced in IMPA1 knockout mice as in
lithium-treated mice
Yeala Sade, Beer- Sheva, Israel
Y. Bersudsky, R. H. Belmaker, G. Agam
LP-01-007
Intracerebroventricular IP3 has behavioral
effects
Yeala Sade, Beer-Sheva, Israel
Y. Bersudsky, R. H. Belmaker, G. Agam
LP-01-008
From animals to human: For ITI-007 transla-
tion of animal data predicts its efficacy and
safety profile in patients with schizophrenia
and other neuropsychiatric diseases
Robert Davis, New York, USA
K. Vanover, S. Mates
LP-01-009
Anomalous asymmetry patterns and related
cognitive level differences in individuals with
the deficit subtype of schizophrenia
Na Li, Chengdu, China
LP-01-010
The medication adherence of blonanserin
after successful monotherapy in chronic
schizophrenic patients over 5 years
Masahiko Nishimoto, Tokyo, Japan
T. Ishigaki, Y. Koyama
LP-01-011
Flexibly dosed paliperidone in non-acute
but symptomatic patients with schizophre-
nia previously unsuccessfully treated with
long-acting injectable risperidone
Andreas Schreiner, Neuss, Germany
P. Bergmans, P.-M. Llorca, G. Corrivetti, B. Co-
sar, P. Cherubin, L. Hargarter
LP-01-012
Flexibly dosed paliperidone palmitate in
non-acute patients with schizophrenia pre-
viously unsuccessfully treated with conven-
tional depot antipsychotics
Andreas Schreiner, Neuss, Germany
P.-M. Llorca, B. Cosar, A. Petralia, P. Bergmans,
P. Cherubin, L. Hargarter
LP-01-013
A randomized, active-controlled rater-
blinded 2-year study of paliperidone pal-
mitate versus investigators‘ choice of oral
antipsychotic monotherapy in patients with
schizophrenia (prosipal)
Andreas Schreiner, Neuss, Germany
K. Aadamsoo, A. C. Altamura, M. Franco,
P. Gorwood, N. G. Neznanov, J. Schronen,
A. Ucok, M. Zink, M. Lahaye, L. Hargarter
